Peptide News Digest

#Azd6234-Comparator

2 stories

Industry · View digest

Novo Nordisk Previews EASD 2026 Data Package: Wegovy Pill Real-World OCTANE Study, Cardiometabolic Outcomes, and Next-Generation Amylin Candidates for the September 28-October 2 Milan Meeting

Novo Nordisk announced Wednesday September 16, 2026 the outline of its data presentations for the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) 2026 in Milan, Italy, September 28 through October 2. Real-world evidence from the OCTANE study will report Wegovy pill (oral semaglutide 25/50 mg) outcomes in adults with overweight or obesity including weight change, treatment switching patterns, and patient-reported outcomes across a large post-launch cohort. Additional EASD abstracts span obesity, type 2 diabetes, cardiovascular disease, kidney disease, and liver-related outcomes. Next-generation amylin candidate presentations include amycretin (long-acting unimolecular GLP-1/amylin dual agonist Phase 2 monotherapy and combination data) and CagriSema (cagrilintide plus semaglutide) follow-through from the earlier Redefine-1 head-to-head miss versus tirzepatide (23% vs 25.5% weight loss at 68 weeks). The EASD cluster also includes AstraZeneca AZD6234 APRICUS amylin data, Zealand-Roche petrelintide ZUPREME-2, and Roche Pharma Day September 28. Novo's Capital Markets Day in London September 21 will precede the EASD meeting by one week.

Clinical Trials · View digest

Ascletis ASC36 Amylin Receptor Peptide Agonist Once-Monthly to Once-Quarterly Phase 1 Enrollment Continues in U.S. Obesity Study

Ascletis Pharma (HKEX: 1672) continued enrollment through early September 2026 in the two U.S. Phase 1 studies of ASC36 (a once-monthly to once-quarterly subcutaneous amylin receptor peptide agonist for obesity) and ASC36_35FDC (a once-monthly subcutaneous fixed-dose combination of ASC36 plus GLP-1R/GIPR peptide agonist ASC35) initiated August 10, 2026 following FDA IND clearance July 5. In head-to-head diet-induced-obesity rat studies, ASC36 monotherapy demonstrated approximately 91% greater relative body weight reduction versus Zealand-Roche's petrelintide and approximately 32% greater versus Eli Lilly's eloralintide. If the Phase 1 tolerability profile confirms preclinical differentiation, ASC36 would enter the amylin analog Phase 2 field alongside Novo Nordisk's cagrilintide-in-CagriSema, AstraZeneca's AZD6234 (Rome EASD 2026 September 28-October 2 readout), Metsera's MET-233i, and the Roche-Zealand petrelintide-plus-enicepatide combination Phase 2 initiation planned mid-2026.